Prademagene zamikeracel
Gene therapy medication
From Wikipedia, the free encyclopedia
Prademagene zamikeracel, sold under the brand name Zevaskyn, is an autologous cell-based gene therapy for the treatment of recessive dystrophic epidermolysis bullosa.[1]
| Clinical data | |
|---|---|
| Trade names | Zevaskyn |
| Other names | EB-101 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625079 |
| License data | |
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Prademagene zamikeracel is a cell sheet-based gene therapy for the treatment of wounds in people with recessive dystrophic epidermolysis bullosa, a rare and debilitating genetic skin disorder caused by mutations in the COL7A1 gene.[3] The therapy utilizes the recipient's own skin cells, genetically engineered to express functional type VII collagen, which are expanded into sheets and surgically applied to chronic wounds.[3]
Prademagene zamikeracel was approved for medical use in the United States in April 2025.[1][2]
Medical uses
Prademagene zamikeracel is indicated for the treatment of wounds in people with recessive dystrophic epidermolysis bullosa.[1]
